Virbac 2021 Annual results indicating increased sales of Stelfonta
https://www.marketscreener.com/quote/stock/VIRBAC-5234/news/Virbac-2021-Annual-results-39830799/
The United States benefited from sustained growth across all product lines, including specialty products, the dental and dermatology ranges, recently launched products (Clomicalm, Itrafungol, Senergy and Stelfonta) and, lastly, the manufacturing of Sentinel Spectrum for Merck. In Latin America, Brazil and Mexico drove growth. Lastly, in Chile, the strong second half-year performance helped us achieve organic growth over the year. In terms of species, the companion animal business was essentially driven by the remarkable double-digit growth of the specialty ranges (including Clomicalm, Movoflex, Stelfonta), etc etc
- Forums
- ASX - By Stock
- Qbiotics
Virbac 2021 Annual results indicating increased sales of...
-
- There are more pages in this discussion • 463 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)